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ABSTRACT: The aim of this work was to study the inﬂuence of
process variables on the quality attributes of pomegranate extract
loaded solid lipid nanoparticles (PE-SLNs) using Plackett−
Burman design. PE-SLN formulations were prepared by hot
homogenization followed by ultra-sonication technique and
evaluated based on the dependent variables that were analyzed
utilizing Statgraphics Centurion XV software. The lipid and
surfactant (type and concentration), co-surfactant concentration,
sonication time, and amplitude were selected as the independent
variables (X1−X7). The dependent parameters were particle size,
polydispersity index, zeta potential, entrapment eﬃciency, and
cumulative drug release (Y1−Y5). Response surface plots, Pareto charts, and mathematical equations were generated to study the
inﬂuence of independent variables on the dependent quality parameters. Out of seven variables, X1, X2, and X6 have the main
signiﬁcant (p value < 0.05) eﬀect on the entrapment eﬃciency, the cumulative drug release, the polydispersity index, respectively,
while particle size was mainly aﬀected by X3, X6 and zeta potential by X1, X3, and X4. Consequently, this screening study revealed that
stearic acid as lipid, Tween 80 as surfactant, as well as sonication with short time and high amplitude can be selected for the
development of PE-SLN formulation with minimum particle size, maximum zeta potential, highest entrapment, and sustained drug
release behavior. Meanwhile, concentrations of lipid, surfactant, and co-surfactant are planned to be scaled up for further
optimization study. In conclusion, the Plackett−Burman design veriﬁed its inﬂuence and signiﬁcance in determining and
understanding both process and formulation variables aﬀecting the quality of PE-SLNs.

■

INTRODUCTION
Since a long time ago, human beings have utilized natural
active ingredients to treat numerous diseases. In recent eras,
products of natural origin have been utilized in the prophylaxis
and treatment of cancer. Although, it has been established that
many of these natural products have a signiﬁcant therapeutic
importance, their low solubility and bioavailability have
rigorously restricted their usage. In the past few periods,
scientists have utilized nanoparticles, produced from natural
products for the treatment and inhibition of several types of
cancers.1
Pomegranate (Punica granatum) has been utilized for
therapeutic purposes long periods ago, particularly, for
treatment of diarrhea, parasitic, and inﬂammatory disorders.2
The traditional importance of pomegranate as a medicinal
plant is now being reinforced by developing scientiﬁc data,
which show that the fruit contains anti-oxidant and antiinﬂammatory activities and may reveal anti-carcinogenic
properties. 3 Owing to its content from polyphenolic
compounds with high antioxidant and free-radical-scavenging
activity, including ﬂavonoids, condensed tannins, and hydro© 2020 American Chemical Society

lyzable tannins (ellagitannins and gallotannins), it is very useful
in the protection against oxidative-stress-related diseases such
as cardiovascular disorders, diabetes, and cancer.2 Antioxidant
activity of pomegranate peels was found to be higher than that
of pomegranate seeds, which could be a great source for the
production of antioxidants with high value.4
Solid lipid nanoparticles (SLNs) are nanoparticles with
submicron particle size (50−1000 nm) that were established as
a substitute carrier system to conventional colloidal systems,
such as emulsions, liposomes, and polymeric microparticles,
and nanoparticles.5 SLNs revealed beneﬁts over emulsions,
liposomes, and polymeric nanoparticles.6 They avoid drawbacks detected with other drug carriers and protect the drug
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Table 1. Observed Values of Responses for 12 Formulations of Pomegranate Extract Solid Lipid Nanoparticles
observed responses (Y1−Y5)
formulation code
F1
F2
F3
F4
F5
F6
F7
F8
F9
F10
F11
F12

particle sizea (nm)
529.5
611.7
1823.0
563.3
599.4
938.4
752.6
321.9
362.7
965.4
1670.0
624.3

±
±
±
±
±
±
±
±
±
±
±
±

8.1
5.6
10.2
9.5
8.7
7.5
13.4
6.4
5.9
8.2
9.9
4.9

PDIa
0.49
0.33
0.59
0.35
0.11
0.80
1.00
0.41
0.42
0.54
1.00
0.34

±
±
±
±
±
±
±
±
±
±
±
±

zeta potentiala (mV)

0.067
0.080
0.012
0.050
0.011
0.007
0.002
0.020
0.049
0.038
0.001
0.030

−22.6
−38.5
−23.1
−21.6
−22.7
−35.7
−25.6
−30.7
−26.3
−29.2
−15.6
−28.8

±
±
±
±
±
±
±
±
±
±
±
±

2.4
2.9
1.8
3.6
4.7
3.5
2.1
3.1
2.3
3.2
2.5
2.4

entrapment eﬃciencya (%)
25.15
55.60
61.11
61.41
15.37
63.74
49.50
29.50
31.50
65.12
23.43
58.71

±
±
±
±
±
±
±
±
±
±
±
±

1.2
3.6
4.2
3.9
1.8
4.4
2.9
1.4
1.8
4.8
1.7
3.6

cumulative releasea (%)
78.01
82.60
69.98
88.30
94.57
87.85
81.80
75.10
71.47
75.95
87.31
74.71

±
±
±
±
±
±
±
±
±
±
±
±

1.8
2.1
1.5
2.3
3.3
2.9
1.6
2.5
1.7
2.6
3.1
2.9

Results are expressed as the mean of three replicates ± SD.

a

Figure 1. Particle size distribution and zeta potential for batch F4.

from chemical degradation compared to that observed with
liposomes.7 Furthermore, SLNs may be developed because of
their advantage of no or least requirement of organic solvents.8
Moreover, SLNs have drawn considerable attention as novel
nanoparticulate carrier systems due to improved delivery and
stability of drugs.6 SLNs consists of a solid lipid matrix at room
temperature and also at body temperature, stabilized by a
surfactant. SLNs have good biocompatibility and biodegradability and also have the ability of incorporating both
hydrophobic and hydrophilic compounds.9 SLNs are commonly developed as suspensions or dry powders. The
suspension can be transformed into a dry product by spray
drying or lyophilization to avoid instability problems.10
Screening several variables that inﬂuence any process is a
tedious study especially if it is carried out by a trial and error
approach. This is due to the fact that it needs a huge number of
experiments that require high cost and consume more time and
eﬀort. It also does not give the researchers the validated and
statistically veriﬁed results.11 For these reasons, Plackett−
Burman design (PBD) is considered as a highly eﬃcient tool to
screen a number of formulation and/or processing variables
and explore the most signiﬁcant variables that can be used in
optimization of the process and ﬁx the other insigniﬁcant at a
low level.12 Several studies had been utilizing PBD in screening
the formulation and/or processing variables in development of
various dosage forms and drug delivery systems such as
controlled release matrix tablets,13 hot melt sustained release
extrudates,14 liposomes,15 niosomes,16 transferosomes,17 protein loaded PLGA nanoparticles,18 PLGA-based nanoparticles,19 alginate-reinforced chitosan nanoparticles,20 Eudragit
microspheres,21 and matrix-type transdermal ﬁlms.22

The emphasis of this study was to design SLNs loaded with
PE and screening the eﬀects of diﬀerent formulation and
processing variables, which were lipid type and concentration,
surfactant type and concentration, co-surfactant concentration,
sonication time, and amplitude on the characteristics of the
prepared PE-SLNs. A PBD was used to determine the critical
parameters that inﬂuence PE-SLN characteristics including
particle size, polydispersity index, zeta potential, entrapment
eﬃciency, and cumulative % release.

■

RESULTS AND DISCUSSION
Preparation of PE-SLNs. Hot homogenization followed
by the ultra-sonication method was carefully chosen for SLN
preparation as it was a reliable, simple, and reproducible
method. Furthermore, it produced a uniform, homogeneous
SLN dispersion,23 without fearing from the incomplete
evaporation of organic solvents that we faced when we tried
the solvent evaporation method.24
To select the best lipids that entrap a high amount of PE,
preliminary studies were done using diﬀerent lipids such as
stearic acid, compritol 888, geleol, and precirol ATO5 in
preparation of PE-SLNs. Stearic acid and precirol ATO5 were
chosen as the lipid core as it displayed the highest entrapment
eﬃciency. In addition, PE-SLNs were stabilized using either
Tween 80 or poloxamer 188 as surfactants and lecithin as a cosurfactant. Based on PBD, the composition of 12 formulations
were prepared.
Evaluation of the Prepared PE-SLNs. Twelve diﬀerent
formulations of PE-loaded SLNs were evaluated for their
particle size (Y1), PDI (Y2), zeta potential (Y3), entrapment
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eﬃciency % (Y4), and cumulative % release after 48 h (Y5), and
the obtained results are shown in Table 1.
The nanoparticles showed variation in size ranging from
321.9 to 1823 nm with PDI values ranging from 0.112 to 1.0.
The size distribution exhibited good unimodal behavior as
deduced in Figure 1. Table 1 and Figure 1 showed the negative
polarity of the prepared PE-SLNs with zeta potential value in
the range of −15.6 to −38.5 mV.
In addition, Figure 2 revealed the transmission electron
microscopy (TEM) analyses of the PE-SLN samples, which

Article

particle size (Y1) = 400.849 − 107.5X1 + 40.875X 2
+ 232.1X3 + 42.462X4 − 2.642X5 + 24.152X6
− 4.483X 7

(1)

A positive value in the model for a response represents a
direct relationship between the speciﬁed factor and the
investigated response, and a negative value indicates an inverse
relationship.26 Statistical analysis of variance of the responses
(Table 2) revealed that the most signiﬁcant variables aﬀecting
Y1 were the surfactant type (X3) with p value equal to 0.049
and the sonication time (X6) with p value equal to 0.044.
Other investigated levels of variables did not have signiﬁcant
inﬂuence on the mean particle size of the prepared PE-SLNs.
Figures 4a and 5a show the Pareto chart and threedimensional response surface plot that displayed the eﬀect of
diﬀerent variables on the particle size of the formulations.
Particle size enlargement was observed with increasing the
sonication time as reported by other investigators.27 This could
be clariﬁed by increasing the temperature of SLNs as the
duration of sonication increased as stated in the study of Zhang
et al.28 In addition, the sonication process simultaneously
reduces the particle size of the individual particles and
potentiates the agglomeration of some ultrasound-activated
particles, which is in good agreement with a previous study.29
The type and concentration of surfactant had a great inﬂuence
on the particle size and stability of nanoparticles. At low
concentrations, the surfactant will not be enough to cover the
surface of nanoparticles and the interfacial tension will be
increased, resulting in particle aggregation and subsequently
enlarged particle size. High concentrations of surfactant may
lead to bridging between nanoparticles and may also cause
toxicity.30 Two diﬀerent surfactants (Tween 80 and poloxamer
188) were evaluated at two levels (3 and 10% w/v). Regarding
the surfactant type (X3), it was found that Tween 80-based
SLNs produce a smaller particle size than those formulations
based on poloxamer. A possible clariﬁcation for this diﬀerence
in particle size may be the inﬂuence of hydrocarbon chain
length diﬀerence of the used surfactants.31 It may also be
attributed to the higher HLB of poloxamer 188 (HLB = 29)
than that of Tween 80 (HLB = 15). This led to the preferential
solubility of Tween in lipid and lipophilic drug subsequently
reducing the interfacial tension at the lipid−water interface.
This enhancement of the emulsiﬁcation process makes the
lipid nanoparticles subdivided and distributed in a ﬁnely small
size, which is in accordance with the previously reported
ﬁnding by Das and co-workers.32

Figure 2. TEM image of pomegranate extract solid lipid nanoparticles
obtained from batch F8.

showed spherical particles with no evident sign of aggregation.
As all the images obtained were similar, we reported only one
image as an example. Furthermore, the entrapment eﬃciency
% was in the range of 15.37−65.12%.
Finally, the cumulative PE release after 48 h reached 94.57%
in F5 which contains the lowest value of both precirol and
poloxamer. Meanwhile, the sustaining PE release was achieved
in F3, which contains the highest value of both stearic acid and
poloxamer. Figure 3a,b displays the release pattern of PE from
all formulations.
Inﬂuence of Investigated Parameters on Particle Size
(Y1). One of the most essential characteristics of the
nanoparticles is the particle size which aﬀects both the release
pattern of the drug and its absorption.25 The mean particle size
(Y1) ranged from 321.9 nm in F8 to 1823 nm in F3 depending
on the variable level selected during production (Table 1). The
model that describes the inﬂuence of variables on the particle
size is

Figure 3. (a) In vitro release of precirol SLNs loaded PE through the cellulose membrane after 48 h. (b) In vitro release of stearic acid SLNs loaded
PE the through cellulose membrane after 48 h.
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Table 2. Statistical Analysis of Variance (ANOVA) of the Responses (Y1−Y5) Results
particle size (Y1), μm
variables

estimate

X1
X2
X3
X4
X5
X6
X7
R2
adj. R2
SEE
MAE

−215.0
163.5
464.2
297.23
−330.3
483.03
−224.13
87.43
65.44
288.01
162.27

p value
0.2656
0.3811
0.0492a
0.1484
0.1179
0.0439a
0.2490

PDI (Y2)
estimate
0.0152
0.1512
0.0678
0.0662
0.0242
0.3842
−0.2335
85.62
60.47
0.17
0.08

zeta potential (Y3), mV

p value

estimate

p value

0.8860
0.2025
0.5319
0.5415
0.8196
0.0180a
0.0783

−5.5667
0.7667
−7.4667
−7.4
0.6667
−0.2333
−0.0333
96.50
90.38
1.97
0.99

a

0.0081
0.5369
0.0028a
0.0029*
0.5890
0.8474
0.9780

entrapment eﬃciency (Y4), %
estimate
−31.873
8.6833
1.9567
−2.92
8.5567
5.3067
−2.48
96.51
90.39
5.73
2.59

p value
0.0007
0.0586
0.5863
0.4276
0.0610
0.1842
0.4955

a

cumulative release (Y5), %
estimate

p value

3.48
−12.92
3.3633
−1.35
−0.1633
−2.3567
−0.8533
91.69
77.14
3.67
1.90

0.1762
0.0037a
0.1880
0.5590
0.9423
0.3288
0.7080

a

Note: Signiﬁcant eﬀect of variables on individual responses. Abbreviations: X1, lipid type; X2, lipid concentration; X3, surfactant type; X4,
surfactant concentration; X5, co-surfactant concentration; X6, sonication time; X7, sonication amplitude; R2, R-squared; adj. R2, adjusted Rsquared; SEE, standard error of estimate; and MAE, mean absolute error.

Figure 4. Pareto charts of all independent variables on (a) particle size, (b) PDI, (c) zeta potential, (d) entrapment eﬃciency %, and (e)
cumulative drug release %.

It was also noticed that there is a direct relationship between
surfactant concentration (X4) and the particle size. This
phenomenon could be explained by increasing intrinsic
thermodynamic instability of the nanoparticle system with
increasing the concentration of surfactant, causing the
adsorption of surfactant on the particle surface.33 Another
explanation explains that increasing the surfactant concentration could cause the rearrangement of the surfactant
molecules to form loops and tails on the particle surface,
leading to the bridging among the SLNs followed by particle
aggregation.34 On the contrary, lecithin concentration (X5)
correlate inversely with the particle size when used as a cosurfactant. It was reported that 10% lecithin is suﬃcient to
produce nanoparticles but, when used in combination with a
surfactant, could yield a lower particle size than when used
alone.35
Although the lipid type (X1) showed an insigniﬁcant eﬀect
on the particle size of the prepared PE-SLNs, stearic acid
containing formulations showed relatively larger particles than
those containing precirol. This diﬀerence in sizes may be due

to a diﬀerence in the melting point of the utilized lipids; hence,
the higher the melting point of a lipid, the larger the size.36 A
high melting point of lipids results in an increase in the
viscosity and leads to an insuﬃcient homogenization, which
causes an ineﬀective reduction of the particle size.37 The same
ﬁndings were observed with lipid concentration (X2) that
played a role in increasing the particle size although it was
insigniﬁcant. This could be explained by the fact that, at higher
lipid contents, the eﬃciency of sonication decreases because of
a higher viscosity of the sample, resulting in larger particles.38
The results obtained are in agreement with those obtained by
Mehnert and co-workers.24 In addition, a high particle
concentration at high lipid contents increases the probability
of particle contact and subsequent aggregation.39 Furthermore,
lack of suﬃcient surfactant to cover the particle surface is the
possible reason for increased particle size.40 On the other hand,
smaller SLNs were obtained by increasing the sonication
amplitude (X7) but it was an insigniﬁcant factor, which is in
agreement with the previously reported results. This may be
21715
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Figure 5. Estimated three-dimensional response surface plot for the eﬀect of the studied variables on (a) particle size, (b) PDI, (c) zeta potential,
(d) entrapment eﬃciency %, and (e) cumulative drug release %.

Inﬂuence of Investigated Parameters on Zeta
Potential (Y3). The surface charge of the SLN dispersions is
considered as a signiﬁcant characteristic of the particles as this
is often controlling the stability behavior when particles
approach each other. The measured potential at the slipping
plane of SLN dispersion is the most appropriate potential,
which is known as the zeta potential.45 Zeta potential (Y3) of
the prepared SLNs formulations ranged from −15.6 mV as in
F11 to −38.5 mV as in F2 depending on the variable levels
selected. All formulations showed a negative zeta potential
since lipid nanoparticles have a negative charge on their surface
due to the presence of terminal carboxylic groups in the
lipids.46 This potential demonstrated that a high potential
value ensures the stability of the SLN dispersions. The linear
model explaining the eﬀects of various variables on zeta
potential (Y3) is

due to the fact that a higher amplitude could deliver more
energy to comminute particles, leading to a smaller size.41
Inﬂuence of Investigated Parameters on Polydispersity Index (Y2). Polydispersity index value was used to
illustrate the monodispersed and polydispersed nature of
nanoparticles. The higher the PDI value, the wider the droplet
size distribution.42 The prepared PE-SLN formulations showed
a variation in PDI values (Y2) ranging from 0.112 as in F5 to
1.0 as in F7 and F11 depending on the variables’ levels used in
the formulations. The best model that describes the eﬀects of
the variables on PDI is
polydispersity index (Y2) = 0.264 + 0.008X1 + 0.038X 2
+ 0.034X3 + 0.009X4 + 0.0002X5 + 0.019X6
− 0.005X 7

(2)

zeta potential (Y3) = 32.4298 − 2.783X1 + 0.1912X 2

Statistical analysis of variance of the responses (Table 2)
showed that the most signiﬁcant independent factor aﬀecting
PDI (Y2) was sonication time (X6) with p value equal 0.018.
Figures 4b and 5b show the Pareto chart and threedimensional response surface plot that displayed the eﬀect of
diﬀerent variables on PDI of the formulations. Since PDI is a
dimensionless measure for the broadness of a particle size
distribution, it was found that increasing X6 leads to a high PDI
value.43 This could be clariﬁed by particle aggregation that
could happen during ultra-sonication technique as previously
mentioned in particle size distribution.29 Quite the opposite,
sonication amplitude (X7) had a negative impact on the PDI
value although this factor is insigniﬁcant. This ﬁnding is in
accordance with the reported results that stated that a high
amplitude intensity leads to uniform distribution, which results
in a low PDI value.41 On the other hand, lipid concentration
(X2) had a positive eﬀect on PDI but it was insigniﬁcant. This
ﬁnding was in agreement with Tiyaboonchai et al., who
reported that a high lipid concentration resulted in a larger
mean particle size and broader size distribution.44 Other
examined variables, which are lipid type (X1), surfactant type
(X 3), surfactant concentration (X4), and co-surfactant
concentration (X5), did not have any signiﬁcant inﬂuence on
the PDI value of the prepared PE-SLNs.

− 3.733X3 − 1.057X4 + 0.005X5 − 0.0117X6
− 0.0007X 7

(3)

Statistical analysis of variance of the responses (Table 2)
revealed that the most signiﬁcant variables aﬀecting Y3 were
the surfactant type (X3) with p value equal to 0.0028, the
surfactant concentration (X4) with p value equal to 0.0029, and
the lipid type (X1) with p value equal to 0.0081. Furthermore,
the lipid concentration (X2) had a positive impact on the zeta
potential, however it was insigniﬁcant.47 Figures 4c and 5c
show the Pareto chart and three-dimensional response surface
plot that displayed the eﬀect of diﬀerent variables on the zeta
potential of the formulations. From the Pareto chart and the
regression equation (eq 3), it was observed that there is an
inverse relationship between X1 and zeta potential of the
formulations. Also, it was noticed that formulations containing
stearic acid showed a relatively higher zeta potential value than
those containing precirol. This may be due to the highly
negative charge of the residual stearic acid distributed at the
surface of SLNs or due to the dissociation of stearic acid in the
aqueous medium.48 The same ﬁnding was observed with the
surfactant type (X3) as the zeta potential value increased by
using Tween 80 rather than poloxamer 188.49 Furthermore,
21716
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external phase of the medium, thus ending up with a low
entrapment eﬃciency.38 Concerning the sonication time (X6)
and amplitude (X7), the entrapment eﬃciency increased when
X6 increased and X7 decreased. This could be explained by the
fact that applying a higher kinetic energy or amplitude on
previously formed lipid particles may bring out the entrapped
drug into the aqueous medium, causing a low entrapment
eﬃciency.54
Inﬂuence of Investigated Parameters on the Cumulative PE Release (Y5). The in vitro release proﬁles of PESLN formulations prepared with precirol compared with that
of stearic acid after 48 h are summarized in Figure 3a,b,
respectively. In vitro release proﬁles of PE-SLN dispersion
showed a biphasic release pattern characterized by a rapid
initial burst drug release followed by sustained release, and this
behavior has been reported for solid lipid nanoparticles.55
Burst drug release is likely due to the attached drug in the
external shell and on the nanoparticle surface, while sustained
release is commonly due to the encapsulated drug in the lipid
core.56 Cumulative release after 48 h ranged from 69.98% as in
F3 to 94.57% as in F5 depending on the variation in the
variable’s levels. The following model (eq 5) describes the
eﬀect of the investigated variables on the cumulative % release:

surfactant concentration (X4) revealed a signiﬁcant impact on
zeta potential as SLNs perfectly covered by a non-ionic
surfactant like Tween 80 and poloxamer 188 tend to remain
stable despite having a lower zeta potential. This could be
attributed to greater steric stabilization and less electrostatic
stabilization. In addition, surface coverage of the SLNs reduces
the electrophoretic mobility of the particles and thus lowers
the zeta potential.40 On the other hand, co-surfactant
concentration (X5) showed a positive insigniﬁcant eﬀect on
the zeta potential. This is due to the ionic nature of lecithin
that broadens the electric double layer surrounding the
nanoparticles and increases the zeta potential.50 The rest of
the investigated variables including the sonication time (X6)
and amplitude (X7) had a non-signiﬁcant eﬀect on Y3.
Inﬂuence of Investigated Parameters on Entrapment
Eﬃciency (Y4). Entrapment eﬃciency refers to the amount,
expressed as percentage, of drug entrapped by the nanoparticles compared to the amount of drug added.48 The
entrapment eﬃciency of the prepared PE-SLN formulations
varied from 15.37% in F5 to 65.12% in F10 due to the
variation in variable combination. The following model can
refer to the eﬀect of the various independent variables on
entrapment eﬃciency:

cumulative % release (Y5) = 101.793 + 1.74X1 − 3.23X 2

entrapment efficiency % (Y4) = 29.293 − 15.937X1

+ 1.682X3 − 0.193X4 − 0.001X5 − 0.118X6 − 0.017X 7

+ 2.171X 2 + 0.978X3 − 0.417X4 + 0.068X5 + 0.265X6
− 0.0496X 7

Article

(5)

(4)

Statistical analysis of variance of the responses (Table 2)
showed that lipid concentration (X2) was the most signiﬁcant
variable aﬀecting the cumulative release (Y5) with p value equal
to 0.0037. Standardized Pareto chart (Figure 4e) and response
surface plot (Figure 5e) showed that increasing the lipid
concentration in the formulation controls the release of PE and
decreases the amount released after 48 h. This could be
explained by increasing the particle size and subsequently
decreasing the speciﬁc surface area and therefore reducing the
release rate.57 In addition, a high lipid concentration leads to a
high medium viscosity and more rigid solidiﬁed nanoparticles,
which would also slow down the drug diﬀusion to the
dissolution medium.54 Despite the non-signiﬁcant eﬀect of the
lipid type (X1) on the drug release, the formulations prepared
with precirol showed a higher release than those prepared with
stearic acid. This could be attributed to the diﬀerence in lipid
melting points previously reported.58 Also, the higher amount
released from precirol particles may also reﬂect the smaller size
of these particles and hence the larger surface area as the size of
precirol nanoparticles represents the smallest of the SLNs
tested.59 Moreover, sonication time (X6) showed a negative
eﬀect on the cumulative release since it led to large particles
and small surface area available for dissolution medium. This is
in accordance with a previous study, which reported the
sustained release of clozapine from tripalmitin-SLNs prepared
by the hot homogenization followed by ultra-sonication
method.60 Furthermore, the obtained results revealed that
the surfactant type (X3) aﬀects insigniﬁcantly the release
proﬁle. The formulations with Tween 80 showed sustaining
release behavior than those with poloxamer 188. This could be
attributed to the diﬀerence in HLB values of two surfactants
where the higher HLB value of poloxamer facilitates the drug
release from the nanoparticles. Finally, neither sonication
amplitude (X7) nor co-surfactant concentration (X5) showed a
signiﬁcant eﬀect on the cumulative release.

Statistical analysis of variance of the responses (Table 2)
displayed that the most signiﬁcant factor aﬀecting the
entrapment eﬃciency (Y4) was the lipid type (X1) with p
value equal to 0.0007. Figures 4d and 5d show the Pareto chart
and three-dimensional response surface plot that displayed the
eﬀect of diﬀerent variables on the entrapment eﬃciency of the
formulations. From Table 1 and the Pareto chart (Figure 4d)
and the response surface plot (Figure 5d), it was noticed that
the formulations prepared with stearic acid showed a higher
entrapment eﬃciency than those prepared with precirol. This
ﬁnding can be explained by the relative hydrophilicity of stearic
acid (HLB = 15), which has a higher potential to solubilize
PE.51 On the contrary, precirol is more hydrophobic lipid
(HLB = 2) and its ability to entrap water soluble drug is low.
In addition, a positive trend with increasing the lipid
concentration (X2) was observed, although it was insigniﬁcant.
This could be due to the fact that a higher amount of lipid
provides an extra space to accommodate an excessive amount
of drug during SLN preparation. This leads to reduction in the
diﬀusion rate of the drug into the external phase as the
viscosity of the lipid phase is higher and thus showed a higher
entrapment eﬃciency.38 Similarly, there is a direct relationship
between the co-surfactant concentration (X5) and the
entrapment eﬃciency, which is in agreement with results of
Rahman et al. 52 On the other hand, the surfactant
concentration (X4) had an inverse relationship with the
entrapment eﬃciency, which might be due to increasing the
particle size. This also explains the negative eﬀect of cosurfactant concentration on the particle size and the positive
eﬀect on the entrapment eﬃciency.53 This may also be clariﬁed
by the partitioning phenomenon, which reported that the
presence of a surfactant with a high concentration leads to a
high solubility of the drug in the external phase, which
increases the partitioning of the drug from the internal to the
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equal to 2n or multiple of 4 in PBD instead of 2 as in the case
of full factorial design.18 Seven diﬀerent variables were used in
SLN formulations using PBD as presented in Table 3.

Finally, with the purpose of achieving the constraints of this
study, we can select stearic acid as lipid, Tween 80 as
surfactant, as well as sonication with short time and high
amplitude for the development of PE-SLN formulation. On the
other hand, concentrations of lipid, surfactant, and cosurfactant can be subsequently examined in a further
optimization study.

Table 3. Independent Variables in Plackett−Burman
Experimental Design

■

levels

CONCLUSIONS
In the present study, screening was done for seven preparation
and processing variables aﬀecting the formulation of solid lipid
nanoparticles loaded with pomegranate extract. PBD was
utilized eﬃciently to distinguish the most signiﬁcant variables
on the quality attributes of the prepared PE-SLNs by the hot
homogenization method followed by ultra-sonication. It was
revealed that lipid type and surfactant type have the main eﬀect
on the entrapment eﬃciency and the particle size, respectively.
Furthermore, the sonication time aﬀects signiﬁcantly both
particle size and polydispersity index. On the other hand, the
cumulative drug release had been aﬀected signiﬁcantly with the
variation in lipid concentration. Therefore, stearic acid can be
used as a lipid to maximize the entrapment eﬃciency and
Tween 80 as a surfactant to minimize the particle size and
increase the zeta potential. In addition, it is preferred to use the
sonication with a high amplitude and short time. To conclude,
out of seven variables, only three, speciﬁcally the concentrations of lipid, surfactant, and co-surfactant, can be scaled up
for subsequent optimization study. This study indicate that
solid lipid nanoparticles can be indeed loaded with the
pomegranate extract with minimum particle size and high
entrapment eﬃciency and controlled release behavior. Yet, full
optimization study and cytotoxicity studies for the optimized
formula of PE-SLNs warrants additional investigation, which
will be the forefront of our laboratory upcoming directions.

independent variables

−1

+1

lipid type, (X1)
lipid concentration, % (X2)
surfactant type, (X3)
surfactant concentration, % (X4)
co-surfactant concentration, mg (X5)
sonication time, min (X6)
sonication amplitude, % (X7)

stearic acid
3
Tween
3
25
10
50

precirol
7
poloxamer
10
150
30
100

This design was established to prepare 12 diﬀerent
formulations of PE-loaded SLNs as shown in Table 4. The
independent variables were lipid type (X1), which was either
stearic acid or precirol, while lipid concentration percent (X2)
was employed either 3 or 7%. Surfactant type (X3) was either
Tween 80 or poloxamer 188 with two diﬀerent concentrations
(X4) either 3 or 10%. In addition, co-surfactant (lecithin)
concentration (X5) was 25 or 150 mg. Also, sonication time
(X6) and amplitude (X7) were 10 or 30 min and 50 or 100%,
respectively. The independent variables were studied for their
eﬀects on the particle size (Y1), polydispersity index (Y2), zeta
potential (Y3), entrapment eﬃciency (Y4), and cumulative %
release after 48 h (Y5).
Preparation of PE-SLNs. SLNs were prepared by the hot
homogenization method followed by ultra-sonication as
described by Dong et al.61 The lipid phase was prepared by
melting stearic acid or precirol, lecithin, and PE at 10 °C above
the lipid melting point, which is 69 °C regarding stearic acid
and 56 °C regarding precirol. The aqueous phase was prepared
by dissolving Tween 80 or poloxamer 188 in deionized water
and heating to the same temperature of the lipid phase. After
that, the hot aqueous phase was gently added into the lipid
phase with constant stirring using magnetic stirrer for 30 min
in a water bath at 10 °C above the melting point of the lipid.
The coarse oil in water emulsion was then sonicated with a
probe sonicator (Vibracell VCX130, Sonics, USA) in an ice
bath at 50 or 100% amplitude for 10 or 30 min. The obtained
dispersions were collected in glass containers and stored in the
refrigerator for further experiments.
Characterization of the Prepared PE-SLNs. The 12
prepared formulations were investigated for particle size,
polydispersity index (PDI), zeta potential, entrapment
eﬃciency, and cumulative % release.
Measurements of Particle Size, PDI, and Zeta Potential.
Particle size as z-average diameter, PDI, and zeta potential of
PE-SLNs were analyzed by the dynamic light scattering (DLS)
technique using a Zetasizer Nano-Zs90 (MPT-Z, Malvern
Instruments Ltd., UK) after dilution with deionized water to
get optimum kilo counts per second (kcps) of 50−200 for
measurements.62 Results were the average of three measurements.
Morphological Analysis. The PE-SLNs were prepared, and
5 μL was placed onto the surface of a 300-mesh copper grid
coated with carbon. Negative staining was performed on the
samples using 2% uranyl acetate (w/v) followed by air-drying
for 15 min and then the excess was removed using ﬁlter paper.

■

MATERIALS AND METHODS
Materials. Pomegranate extract (PE) from pomegranate
fruit (peel) containing ≥30% punicalagin was purchased from
Shaanxi Ciyuan Biotech Co., Ltd. (Shaanxi, China). Stearic
acid, disodium hydrogen phosphate, and potassium dihydrogen phosphate were purchased from El-Nasr Pharmaceutical
Chemicals Co. (Cairo, Egypt). Precirol ATO5 was donated as
a gift from Gattefosse (Cedex, France). Tween 80, lecithin, and
poloxamer 188 were generously donated by Egyptian International Pharmaceutical Industries Co., EIPICO, (10th of
Ramadan City, Egypt). Dialysis tubing cellulose membrane
with a molecular weight cutoﬀ of 12,000 Da was purchased
from Sigma-Aldrich (St. Louis, MO, USA). All other chemicals
were of analytical grade.
Methods. Experimental Screening Design. Development
of pharmaceutical formulations conventionally is based on
consuming time and energy by varying one factor at a certain
time while keeping other factors constant. On the other hand,
using experimental design (DOE) technique allows examining
a large number of variables at the same time with a little
number of experimental runs. Screening design is the greatest
inﬂuential DOE methods that identify the most important
factors in the pharmaceutical development. PBD is one of the
commonly used screening designs, which screens a large
number of factors and determines the critical one in a minimal
number of runs with a high degree of precision. Generally, a
number of runs required to examine the signiﬁcant eﬀects are
21718

https://dx.doi.org/10.1021/acsomega.0c02618
ACS Omega 2020, 5, 21712−21721

ACS Omega

http://pubs.acs.org/journal/acsodf

Article

Table 4. Formulations Composition of Solid Lipid Nanoparticles Loaded with Pomegranate Extract as Suggested by Plackett−
Burman Design
formulation code

lipid type

lipid (%)

surfactant type

surfactant (%)

co-surfactant (mg)

sonication time (min)

sonication amplitude (%)

F1
F2
F3
F4
F5
F6
F7
F8
F9
F10
F11
F12

precirol
stearic acid
stearic acid
stearic acid
precirol
stearic acid
precirol
precirol
precirol
stearic acid
precirol
stearic acid

7
3
7
3
3
7
7
3
7
7
3
3

Tween
Tween
poloxamer
poloxamer
poloxamer
Tween
poloxamer
Tween
Tween
poloxamer
poloxamer
Tween

10
3
10
10
3
3
3
3
10
3
10
10

25
25
25
150
25
25
150
150
150
150
25
150

10
10
30
10
10
30
30
30
10
10
30
30

50
50
100
100
100
100
50
100
100
50
50
50

the model. A p value less than 0.05 indicates the signiﬁcance of
model terms. The statistical software Statgraphics Centurion
XV software, version 15.2.05 (StatPoint, Inc., Warrenton, VA)
was used for the regression analysis and the graphical
presentation. After analysis of the data, the linear correlations
for each response were obtained in terms of coded variables to
quantify response values.

The stained grids were then probed using transmission
electron microscopy (TEM) (model JEM-2100, Jeol, USA)
to visualize the morphology of the nanoparticles operating at
an acceleration voltage of 200 kV.63
Determination of the Entrapment Eﬃciency (EE %).
Entrapment eﬃciency % was determined by measuring the
amount of free drug in the aqueous phase after separation of
the system using a centrifugation method. PE-SLN dispersion
was centrifuged at 12,000 rpm and 4 °C for 1 h using a freeze
centrifuge (2-16KL, Sigma Laborzentrifugen GmbH, Germany), and then the supernatant was collected to measure the
free drug concentration after suitable dilution with a fresh
phosphate-buﬀered saline (pH 7.4).64 The drug concentration
was measured at 265 nm using an ultraviolet−visible
spectrophotometer (V-630, Jasco, Japan).65 The percent of
entrapped drug was calculated according to eq 6:62
EE (%) =

Winitial drug − Wfree drug
Winitial drug
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(Figures S1−S10) The estimated three-dimensional
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